Every year, millions of people struggle with wounds that take weeks or even months to heal. These wounds can lead to infections, longer hospital stays, and higher healthcare costs. Finding better treatment options has become a priority for researchers and healthcare providers. Cleveland-based startup Auxilium Health is working on a new approach, and its latest funding round marks an important step in bringing that technology closer to patients.
Auxilium Health secures $3.4 million in seed funding
Auxilium Health has raised $3.4 million in an oversubscribed seed funding round to accelerate the development of its Aer™ biomaterial platform. The company announced that the new funding will help move its technology toward FDA clearance and first-in-human studies, while supporting product development and company growth.
The funding follows the company’s earlier pre-seed financing and reflects continued investor confidence in its mission to improve wound care through advanced biomaterials.
A new approach to chronic wound care
Auxilium Health develops biomaterials designed to improve the healing environment for chronic and difficult-to-treat wounds. The company’s Aer™ platform focuses on creating conditions that support healthy tissue regeneration while reducing the impact of harmful bacteria that can interfere with the healing process.
Chronic wounds remain a major healthcare challenge worldwide. Patients with conditions such as diabetes, poor circulation, or limited mobility often experience wounds that heal slowly. These wounds increase the risk of infection and can place a significant burden on patients and healthcare systems.
Auxilium Health aims to address this challenge by developing biomaterials that support the body’s natural healing process instead of relying only on conventional wound dressings.
Funding will support key development milestones
The newly raised capital will allow the company to continue advancing its technology through important regulatory and development stages. According to Auxilium Health, the investment will support activities leading toward FDA clearance and first-in-human clinical studies.
The company also plans to expand its research and development efforts as it works to transform years of scientific research into products that can be used in clinical settings.
Reaching these milestones is an important step for any medical technology company. Regulatory progress and clinical evaluation help demonstrate whether a new technology can meet safety and performance standards before it becomes available for wider use.
CEO highlights the company’s mission
Isaiah Kaiser, PhD, Co-founder and Chief Executive Officer of Auxilium Health, said the company’s goal is to develop bio-selective materials that give regenerative cells an advantage over harmful bacteria during the healing process. He noted that this approach could help improve healing outcomes for patients with chronic wounds.
His comments reflect the company’s broader mission of combining advanced materials science with regenerative medicine to address one of healthcare’s most persistent challenges.
Building on scientific research
Auxilium Health’s technology is based on years of scientific research focused on improving wound healing through innovative biomaterials. Rather than treating wounds with a one-size-fits-all approach, the company is developing materials designed to support the body’s natural repair mechanisms.
The Aer™ biomaterial platform represents the company’s core technology and serves as the foundation for its future product pipeline. With the latest funding, Auxilium Health can continue refining this platform while preparing for the next phase of development.
Looking ahead
The demand for better wound care solutions continues to grow as healthcare providers seek more effective ways to treat chronic and complex wounds. Innovations that support faster healing and improve patient outcomes have the potential to reduce complications and lower the overall cost of care.
With its oversubscribed $3.4 million seed funding round, Auxilium Health has strengthened its position to advance the Aer™ biomaterial platform through regulatory development and toward first-in-human studies. As the company continues its research, it aims to bring a new generation of wound care technology closer to the patients and clinicians who need better treatment options.
